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Background: Quantitative description of dose–response of a drug for complex systems is essential for treatment of
diseases and drug discovery. Given the growth of large-scale biological data obtained by multi-level assays, computational
modeling has become an important approach to understand the mechanism of drug action. However, due to
complicated interactions between drugs and cellular targets, the prediction of drug efficacy is a challenge, especially for
complex systems. And the biological systems can be regarded as networks, where nodes represent molecular entities
(DNA, RNA, protein and small compound) and processes, edges represent the relationships between nodes. Thus
we combine biological pathway-based network modeling and molecular docking to evaluate drug efficacy.
Results: Network efficiency (NE) and network flux (NF) are both global measures of the network connectivity. In
this work, we used NE and NF to quantitatively evaluate the inhibitory effects of compounds against the
lipopolysaccharide-induced production of prostaglandin E2. The edge values of the pathway network of this
biological process were reset according to the Michaelis-Menten equation, which used the binding constant
and drug concentration to determine the degree of inhibition of the target protein in the pathway. The combination of
NE and NF was adopted to evaluate the inhibitory effects. The dose–response curve was sigmoid and the EC50 values of
5 compounds were in good agreement with experimental results (R2 = 0.93). Moreover, we found that 2 drugs produced
maximal synergism when they were combined according to the ratio between each EC50.
Conclusions: This quantitative model has the ability to predict the dose–response relationships of single drug and drug
combination in the context of the pathway network of biological process. These findings are valuable for the evaluation
of drug efficacy and thus provide an effective approach for pathway network-based drug discovery.
Keywords: Dose–response modeling, Drug combination, LPS-induced PGE2 production, Pathway networkBackground
The dose–response relation is a key topic in pharmacology.
How to predict the efficacy of a compound for a system
(protein, biological process, cell, tissue, organ and the body)
is critical for drug discovery. The drugs (magic bullets)
developed in the past decades were designed to selectively
target a specific protein. However, when a single drug is* Correspondence:
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creativecommons.org/publicdomain/zero/1.0administered and enters the body, interaction with 1 or
more cellular targets is possible [1, 2]. A drug may produce
multiple effects in the system through interacting with mul-
tiple cellular targets, which is called “polypharmacology”
[2, 3]. The pathogenesis of complex diseases such as cardio-
vascular disorders and diabetes is related to a lot of genetic
and environmental factors [4, 5]. The human body is a
complicated, integrated and networked biological system.
And drugs which selectively target 1 protein cannot treat
complex diseases effectively due to the robustness and re-
dundancy of the biological system [6–11]. Meanwhile,
multi-target drug therapies may be more effective than in-
dividual high-affinity drugs for complex diseases [12].
Nevertheless, the more drugs administrated or more targets
with which drugs can interact, the more complicated thele distributed under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any medium,
d. The Creative Commons Public Domain Dedication waiver (http://
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ficacy is a challenge, especially for complex systems.
When 2 or more drugs are administrated in combination,
the interactions among drugs would add a further compli-
cation to the prediction of the dose–response relation of
drug combination. Generally, the drug interaction would
generally produce 1 of 3 different effects: synergism, antag-
onism and additive effect [13, 14]. Synergism means that
drug combination could produce exaggerated effect, and
antagonism could reduce the total effect. Synergism is espe-
cially important in clinical applications since it allows the
use of smaller amounts of drugs and thus reduces the ad-
verse effect or toxicity [14–17].
We have developed a pathway network-based approach
to evaluate the efficacy of a compound against biological
processes, such as blood clotting [18] and platelet aggrega-
tion [5]. Recently, we used this method for virtual screening
of active compounds for the inhibition of lipopolysacchar-
ide (LPS)-induced prostaglandin E2 (PGE2) production
[19]. In this work, we demonstrate an advance in the quan-
titative modeling of dose–response and drug combination
based on the pathway network of LPS-induced PGE2 pro-
duction. PGE2 is the principal inflammation mediator,
which could participate in many pathological processes
[20–22]. The production of PGE2 can be regarded as a bio-
marker of inflammation. Generally, the pathway of LPS-
induced PGE2 production was modeled as a network. And
the binding affinity of a compound to a protein in the path-
way network was assessed by molecular docking. The dock-
ing results had influence on the edge weights by relating
them to enzyme efficiency via Michaelis-Menten kinetics.
The effect of a compound on the entire network, andFig. 1 The pathway network of LPS-induced PGE2 production. Circle and d
proteins for molecular docking are marked as green diamondsthus, in this particular case, the production of PGE2, was
assessed by using the network connectivity measures
(network efficiency and network flux). By integrating mo-
lecular docking and network analysis, network efficiency,
network flux and their combination can quantitatively de-
scribe the inhibitory effects of compounds. Moreover, the
efficacy and synergism or antagonism of the combination
between 2 compounds were also evaluated.
Results
Pathway network of LPS-induced PGE2 production
The pathway network of LPS-induced PGE2 production
(Fig. 1) comprised 30 nodes and 38 edges (arrows), where
nodes represented proteins and small molecules involved in
the process of LPS-induced PGE2 production, and edges
meant that the node in front of the arrow was downstream
in the pathway. This network was a scale-free and small-
world network, which were 2 typical characteristics of bio-
logical networks [23]. It indicated that the network can
have strong stability and can resist random attacks [23, 24].
However, it would be vulnerable for targeted attacks, such
as selective drugs. Therefore, it offered an opportunity for
us to develop drugs to treat inflammation-related diseases,
especially multi-target drugs and drug combination to sim-
ultaneously block multiple targets with varying degrees.
Network efficiency and network flux
Network efficiency was first proposed by Latora V. and
Nagurney A. to measure the importance of a node in a net-
work when the node was removed [25, 26]. Then it was
adopted by our lab to evaluate the efficacy of a drug against
blood clotting cascade [18] and platelet aggregation [5]. NEiamond represent small molecule and protein, respectively. The target
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can reflect the integrity of the network. NE was defined as
the sum of the shortest path lengths between each node in
the network. Thus in the calculation of NE, all shortest
paths between a node and other N-1 nodes counted (N was
the number of nodes in the network). However, it cannot
reflect the different weightiness of the node because all
nodes were calculated N-1 times [5]. Actually the further
downstream a node located in the pathway network, the
more important it would be. Thus network flux was pro-
posed to calculate the shortest paths between all other
nodes and the exit node of the pathway network in our pre-
vious work [5]. The combination of NE and NF took into
account the different importance of the node, thus it can be
used to predict the potencies of compounds against platelet
aggregation [5].
The degree of decrease of NE (NEd) and NF (NFd), and
the geometric mean of NEd and NFd (NEF) were all indi-
cators of the network connectivity. In this work, we stud-
ied 5 active compounds (Fig. 2) extracted from Reduning
Injection which was a widely used Chinese medicine pre-
scription [19]. The activities of 5 compounds against LPS
induced PGE2 production at different concentrations were
predicted. However, NEd, NFd and NEF had different
accuracies for the predictions, as shown in Fig. 3. Caffeic
acid and Scopoletin were the 2 of the most potent com-
pounds, so the 2 compounds were picked out as examples.
In the case of Caffeic acid (Caa), the predictions of NEd
were lower than the in vitro experimental results, while the
predicted inhibition rates by NFd were higher than ex-
perimental results (Fig. 3a). It was more complicated
for Scopoletin (Sco): the model had higher predictions
at low concentrations and lower predictions at high
concentrations by NEd, while it was the direct opposite
of predictions by NFd (Fig. 3b). However, the model
gave good agreements between predictions by NEF and
experiment results in all cases. Therefore, NEF was a
better evaluation indicator for this system and was used
in further evaluations.Fig. 2 Structures of 5 active compoundsDose–response curve
The shape of the dose–response curve was important to
evaluate the efficacy of a compound. All predicted and ex-
perimental dose–response curves were sigmoid. Table 1
listed the parameters of fitted dose–response curves of 5
active compounds according to the predictions by NEF.
The Emax and Emin were close to 100 % and 0, respectively.
And the correlation coefficients were higher than 0.999, es-
pecially for Caa and Sco (Figs. 4a, b). Moreover, the pre-
dicted EC50 values of 5 active compounds well matched
with the experiment values (R2 = 0.93, Table 1), which indi-
cated that the prediction model by NEF would be reliable.Drug combination and dose–response surface
This approach can also evaluate the combination of 2
or more compounds. There would be 3 effects for drug
combination: synergism, additive effect and antagon-
ism. The combination index (CI) proposed by Chou T.
C. was adopted to quantify the synergic degree of drug
combination [13]. When 2 drugs both existed in the
system, it would produce a dose–response surface (DRS).
Fig. 5a showed the DRS of the combinations between
Caa and Sco in different doses. A series of drug com-
bination can have the same effects on the system,
which can be described by the isobologram (Fig. 5b).
Each dose pairs on the isobologram represented pos-
sible combinations that produced the equivalent effect.
In the case of combination of Caa and Sco, it was a typ-
ical synergistic effect. However, each drug pair in the
isobologram differed in degree of synergism. The stars
in Fig. 5b pointed out the optimal combination for each
degree of inhibition. And we found that the dose ratios
of 2 compounds for maximal synergism were nearly the
same with the ratio between each EC50. Therefore, the
experimental inhibition rates of 6 combinations of Caa
and Sco with the ratio between each EC50 value were
determined. And the results agreed well with the pre-
dictions (R2 = 0.84, Fig. 5c).
Fig. 3 The linear fitting between predicted efficacy and in vitro experimental results. (a) Caffeic acid; (b) Scopoletin. The black square, red dot and blue
triangle represent the predictions of NEd, NFd and NEF, respectively
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The pathway of a biological process is a minimal biosystem
with a specific function and can be abstracted as a network.
The network properties can relate with the state of the
biosystem to a certain extent, especially for biomarkers
related to diseases [5]. Thus the influence on the pathway
network of a compound can be used to evaluate the efficacy
[5, 18, 23, 27–29]. These results demonstrated that the de-
gree of the decreases of NE, NF and NEF were measures of
inhibition of a drug against LPS-induced PGE2 production.A drug could target multiple proteins in the biological
pathway, and a drug combination could produce synergistic
or antagonistic effect in different extent through multi-
target interactions [14, 19, 30]. Synergism is useful in
illuminating mechanisms of drug action and exploring
computational models to predict new drug leads in drug
discovery. The dose–response surface and isobologram are
2 practical tools. Moreover, the combination index is a con-
venience for researchers to determine whether synergism,
additive effect, or antagonism exists in a drug combination.
Fig. 4 Dose–response curve. (a) Caffeic acid; (b) Scopoletin










Caffeic acid 99.49 0.28 30.20 0.98 0.99994 17.35
Coumarin 99.99 0.85 52.95 1.12 0.99996 49.14
Isochlorogenic
acid B
111.20 −3.63 116.16 0.56 0.9998 96.82
Protocatechuic
acid
101.18 −1.46 42.82 0.77 0.99995 46.34
Scopoletin 100.72 0.60 45.48 1.01 0.99994 38.46
aEmax and Emin were the top and bottom asymptotes of the response,
respectively. bEC50 and EC50e were the concentration of inhibitor at
half-maximal effect calculated by predictions and experimental results, respectively
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LPS-induced PGE2 production are unclear now since the
biological system of the cells or organism is complicated.
Our recent works indicated that most active compounds
would have polypharmacology according to drug-target
network [30]. However, the computational approach in this
work generally does not need to know about the exact
mechanism, which could broaden the scope of application,
especially for complex systems.
Although in the above text the predictions of this
model agreed well with the experimental results, it
would be necessary to note that this approach should
require several conditions to obtain reasonable predic-
tions. First, the pathway of a biological process should
be as fully accurately as possible. The calculations of
Fig. 5 Drug combination. The dose–response surface (a) and isobologram (b). (c) was the comparison between predicted efficacy and
experimental inhibition
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Table 2 14 target proteins for molecular docking
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of the pathway network. The information of the path-
way of LPS induced PGE2 production is abundant and
this system has been reviewed in literatures and data-
bases (described in the section of Construction of the
pathway network of LPS-induced PGE2 production).
However, when others apply this approach in this work
to other systems, they need to be very careful. When a
pathway has low completeness or lacks sufficient anno-
tations, the predictions would have large deviations.
Second, the structures (determined by X-ray or NMR)
of most target proteins in the pathway should be known.
It's best to obtain ligand-protein complex structure and
thus the binding site can be defined as the space which was
occupied by the ligand. Beyond that, the binding energy cal-
culated by molecular docking or molecular dynamics simu-
lation should be accurate. The binding predictions from
molecular docking are subject to a margin of error due to
the principle and method of the calculation. However,
we can try to reduced the error. For example, we used
the most commonly used software AutoDock4 and
adopted the validated protocols whose predictions had
been validated by experimental results in our previous
works [5, 18]. Big errors of binding predictions may
affect the calculation of edge values and then reduce
the accuracies of the calculation of NE and NF. Fur-
thermore the predictions of inhibition rates of drugs
would have big errors. Finally, the prediction model
should be validated by experiments. The known active
compounds can be used as training set to adjust the pa-
rameters of the predicting model.Target Protein name UniProt ID PDB ID
TLR4 toll-like receptor 4 O00206 4G8A
PGES Prostaglandin E synthase O14684 3DWW
TAK1 MAP3K7 O43318 2YIY
AP-1 Transcription factor AP-1 P05412 1FOS
NF-κB Nuclear factor NF-kappa-B P19838 3GUT
ERK ERK-1 P27361 2ZOQ
COX-2 COX-2 P35354 3LN1*
JNK c-Jun N-terminal kinase P45983 3PZE
MKK4/7 mitogen-activated protein kinase
kinase 4
P45985 3ALN
MKK3/6 mitogen-activated protein kinase
kinase 6
P52564 3FME
p38 p38 MAP kinase P53778 1CM8
MEK1/2 mitogen-activated protein kinase
kinase 1
Q02750 3DY7
TRAF6:RIP1 RIP1 Q13546 4ITJ
TRAF6 TNF receptor-associated factor 6 Q9Y4K3 1LB5
*The structure of COX-2 was modeled by computer homology modeling based
on the structure of Mus musculus (PDB: 3LN1) by SWISS-MODEL [48], since
there was no human structure available and the identities between the two
proteins from human and Mus musculus was 87 %Methods
Construction of the pathway network of LPS-induced
PGE2 production
The pathway network of LPS-induced PGE2 production
was constructed in our recent work [19] according to
the information extracted from KEGG pathway data-
base [31], Reactome [32], and literatures [33–40]. Gen-
erally, LPS-induced PGE2 production was involved in 2
pathways: Toll-like receptor signaling pathway (ID:
map04620 in KEGG pathway database) and NF-kappa
B signaling pathway (map04064). First, LPS can interact
with CD14 and the complex facilitates the recognition
of LPS stimulation by TLR4. Then the signaling is divided
into MyD88-dependent and TRIF-dependent pathways.
MyD88 and TRIF can activate transcription factors
such as IRF-5, NF-kappa B and AP-1 in the down-
stream pathway. In particular, Eliopoulos A. G. and
colleagues contributed the pathway of CREB, a key
regulator of COX-2 transcription [39]. Finally, the path-
way comprised 30 nodes and 38 edges (Fig. 1). Cytos-
cape 2.8 was used to visualize the network andcalculate the network properties by Network Analysis
plugin [41].Molecular docking
There were 14 important proteins (Table 2) which can be
used for molecular docking. When a protein had multiple
X-ray or NMR structures in RCSB Protein Data Bank
(http://www.rcsb.org/pdb/home/home.do), there were sev-
eral criteria to choose the most suitable structure. First,
the structure had more complete peptide chains. Second,
the resolution of the structure should be as high as pos-
sible. Third, it’s better that the structure had a ligand. The
X-ray or NMR structures were downloaded from RCSB
Protein Data Bank and treated to suitable for molecular
docking by Autodock4 [42, 43] according to the protocols
described in previous works [5, 19, 44]. The energy grid
was a 20 × 20 × 20 Å cube centered on the occupied
space of the original ligand with a spacing of 0.375 Å be-
tween the grid points. The maximum number of energy
evaluations was set to 2.5 × 107. The AD4score function
was used to evaluate the affinity between compound and
protein, and the docking score was pKi.Calculation of network efficiency and network flux
According to Michaelis-Menten equation and the law
of mass action, the rate equation in presence of 1 non-
competitive inhibitor I was:
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1
1 þ KmS½ 
 
1 þ I½ KI
 
¼ vo  1
1 þ I½ KI
  ð1Þ
where Km, KI, [S] and [I] are Michaelis constant, inhib-
ition constant of I, concentration of substrate S and in-
hibitor I; v0 is the activity of the enzyme without
inhibitor [45]. Thus we defined the fraction of affection
(fa) to quantify what the percentage the enzyme was
inhibited:
f a ¼ 1 −
v
vo
¼ 1 − 1
1 þ I½ KI
ð2Þ
When 2 mutually exclusive inhibitors (X and Y) both
existed in the system, fa would be [45]:
f a ¼ 1 −
v
vo
¼ 1 − 1




In the pathway network, the value of an edge (EV) repre-
sented the resistance in signal transduction. That is, when a
target protein was inhibited, the value of the edge which
came out from the target protein would enlarge to accom-
modate it. We arbitrarily set the initial (default) EV for each
edge as 1. We arbitrarily assumed that the most potent in-
hibitor can block the target 99.5 %, thus we defined the
highest EV as 200 (1/(1–99.5 %)). Accordingly, the EV at
different concentration of inhibitor I would be:
EV ¼ 102:303  f a ¼ 10
2:303  1− 1





2:303  1 − 1





when 2 inhibitors both existed.
Network efficiency and network flux were both mea-
sures of the network connectivity [5, 18, 26]. NE was de-
fined as the sum of the reciprocals of the shortest path








NF was defined as the sum of the reciprocals of the
shortest path lengths between other nodes and the exit






where dij is the length of the shortest path between
nodes i and j . The calculation programs of NE and NF
were written in C++ language using the Dijkstra
algorithm.
In order to evaluate the influence of a compound on
the pathway network, we defined the NEd as the degree
of decrease of NE as following:
NEd ¼ NEmax − NE
NEmax − NEmin
 100% ð8Þ
where NEmax and NEmin are the maximal and minimal
NE when all EVs are set as 1 and 200, respectively. Simi-
larly, the NFd was defined accordingly:
NFd ¼ NFmax − NF
NFmax − NFmin
 100% ð9Þ
Finally, we defined the NEF as the geometric mean of
NEd and NFd to evaluate the impact of a compound on






Fitting of dose–response curve
Typically, the dose–response relation can be simulated
by the following equation [46]:
y ¼ Emax − Emax − Emin
1 þ I½ EC50
 n ð11Þ
where Emax and Emin are the top and bottom asymptotes of
the response, y is the inhibition rate when the concentra-
tion of the inhibitor is [I], EC50 is the concentration of in-
hibitor at half-maximal effect, and n is the slope parameter
like the Hill coefficient [47]. The fitting of computational
efficacy or experimental results versus the concentration of
the inhibitor was performed and the correlation coefficient
was used to evaluate the reliability of the model.
Combination index
The effect of the combination of 2 drugs may be simple
additive, exaggerated (synergistic) or attenuated (antag-
onistic). In order to quantify the synergism or antagon-
ism for 2 drugs (D1 and D2), Chou T. C. introduced the
term combination index [13]:





where CI <1, =1 and >1 indicated synergism, additive ef-
fect and antagonism, respectively. (Dx)1 and (Dx)2
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can inhibit the system x %. (D)1 and (D)2 were the con-
centrations when D1 and D2 in combination can inhibit
the system x %.Experimental
RAW264.7 Cell experiments
All compounds for in intro test were purchased from Na-
tional Institute for Food and Drug Control (Beijing, China).
Lipopolysaccharide (LPS) was purchased from Nanjing
Baikang Biological Technology Co., Ltd. (Nanjing PR
China). The inhibitory activities of compounds against
LPS-induced PGE2 production were determined in
RAW246.7 cells (Cell Culture Center of the Chinese
Academy of Medical Sciences, Beijing, China). First,
RAW246.7 cells were cultured in high-glucose Dulbecco’s
Modified Eagle’s medium (DMEM, Gibco, Carlsbad, USA)
which contained streptomycin (100 μg ml−1), penicillin
(100 U ml−1) and 10 % (v/v) fetal bovine serum (FBS,
Sijiqing, Deqing, Hangzhou, China) at 37 °C in a hu-
midified incubator containing 5 % CO2. Second, the
cell viability was determined by MTT assays to evaluate
the cellular toxicity of compounds. RAW246.7 cells
were plated in 96-well plates (4 × 104 cells/well) over-
night and treated 24 h with various concentrations of
compounds in FBS-free DMEM. MTT (5 mg mL−1)
was added in each well and the cells were incubated for
4 h at 37 °C. Then the standard protocol of MTT assays
was adopted to determine the cell viability by Spectra-
Max M2e Microplate Reader (Molecular Devices,
Menlo Park, USA). Third, RAW264.7 cells were pre-
treated with various concentrations of compounds or
positive drug (Celecoxib) for 1 h. Then LPS (final con-
centration 1 μg ml−1) was added and the cells were in-
cubated for 16 ~ 18 h. The concentration of PGE2 was
measured by Prostaglandin E2 EIA kit (Enzo Life Sci-
ences, Farmingdale, NY, USA). The experiments were
repeated 3 times at each concentration of each com-
pound. The inhibition rate of a compound against LPS-
induced PGE2 production was calculated by:
Inhibition rate ¼ 1 − C drug − C controlð Þð Þ




where C(control) was the background concentrations of
PGE2. C(drug) and C (model) represented the concen-
trations of PGE2 when the RAW246.7 cells were incu-
bated with drug or DMSO and then stimulated by LPS,
respectively.Conclusions
In this study, we developed a quantitative model to predict
the dose–response curves of single drug and drug combin-
ation based on the pathway network of LPS-induced PGE2
production. The network efficiency and network flux are
both measures of the connectivity of the pathway network.
And thus the degrees of the decrease of NE, NF and NEF
could evaluate the efficacy of a drug to the biological sys-
tems. By integrating molecular docking and network ana-
lysis, the dose–response relationships of 5 compounds
against LPS-induced PGE2 production were evaluated and
the predictions agreed well with experimental results. Fur-
thermore we explored the dose–response relationships of
drug combinations to study the synergism. Moreover, iden-
tifying novel effective drug combinations or multi-target
agents is a new trend in drug discovery. Actually, the herb
medicines are the natural combinations of active com-
pounds. This computational method can be used to quanti-
tatively evaluate the efficacy of a mixture of 2 or more
drugs, even herb medicines. The increasing of the complex-
ity of multiple omics data sets requires more effective ap-
proaches for drug screening. And computational modeling
is an indispensable tool for understanding dose–response
relationship and mechanisms of a drug or drug combin-
ation. This work would provide a new computational ap-
proach to evaluate drug efficacy before clinic trials and
screen optimal combination for drug discovery when a bio-
logical system/process has a well-defined pathway.
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